Mark A. Demitrack

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition.

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.

Effects of duloxetine on painful physical symptoms associated with depression.

Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome.

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.

Can monoamine-based therapies be improved?

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Clinical methodology and its implications for the study of therapeutic interventions for chronic fatigue syndrome: a commentary.

Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial.

Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment.

Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial.

Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis.

Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data.

Reply regarding "efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial".

Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study.